Skip to main content
PBF logo

PBF — Investor Relations & Filings

Ticker · 1760 ISIN · TW0001760007 LEI · 54930078VUU2LBPR2729 TW Manufacturing
Open in API
Filings indexed 1,562 across all filing types
Latest filing 2022-05-12 Interim / Quarterly Rep…
Country TW Taiwan
Listing TW 1760

About PBF

http://www.pbf.com.tw

Panion & BF Biotech Inc. is a biotechnology company focused on pharmaceutical research, development, and manufacturing. Founded in 1976, the firm operates across several core sectors, including new drug innovation, medical aesthetics, and nutritional supplements. It is recognized for its "Total Aging Management" strategy, which addresses the health needs of an aging population through a diverse product portfolio. Key offerings include treatments for chronic kidney disease, specifically phosphate binders, as well as dermatological drugs, hair care solutions, and rapid diagnostic technologies. The company integrates clinical-grade pharmaceutical standards into its consumer health and aesthetic products, serving markets in chronic disease care and preventative wellness.

Recent filings

Filing Released Lang Actions
111年第1季資產負債表
Interim / Quarterly Report Classification · 95% confidence The document contains a consolidated balance sheet with detailed financial data for multiple dates, including the first quarter of the year 111 (Taiwan calendar, corresponding to 2022). It includes comprehensive financial statement items such as assets, liabilities, equity, and detailed breakdowns. The document length is 4087 characters, which is relatively short but contains substantive financial data, not just an announcement or a link to a report. The presence of actual financial figures and accounting items indicates this is a financial report for a period shorter than a full fiscal year, specifically a quarterly report. Therefore, the document is best classified as an Interim / Quarterly Report (IR). Q1 2022
2022-05-12 Chinese
公告本公司設置公司治理主管
Board/Management Information Classification · 95% confidence The document is a short announcement (709 characters) about the appointment of a new corporate governance officer (公司治理主管) at the company 寶齡富錦. It details the personnel change, including the new appointee's name and position, and the effective date. There is no financial data, no report attached or referenced, and no mention of a meeting or voting results. This fits the category of Board/Management Information (MANG), which covers announcements of changes in senior management or board members. The document is not a full report, nor an announcement of a report publication, so it is not RPA or RNS. Therefore, the correct classification is MANG with high confidence.
2022-05-11 Chinese
公告本公司111年第1季合併財務報告
Interim / Quarterly Report Classification · 95% confidence The document is a public announcement from a listed company (1760 寶齡富錦) reporting its consolidated financial results for the first quarter of the year 111 (Taiwan calendar, equivalent to 2022). It includes detailed financial figures such as revenue, gross profit, operating profit, net profit, earnings per share, total assets, liabilities, and equity for the period 111/01/01 to 111/03/31. The document mentions the board meeting date and audit committee approval date, indicating it is a formal financial report for a period shorter than a full fiscal year. The content is substantive financial data and analysis for a quarterly period, not just an announcement or a certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). The document length is 905 characters, which is sufficient for a short quarterly report and not merely a report publication announcement. Q1 2022
2022-05-11 Chinese
111年4月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a brief financial disclosure from a listed company, providing data on loan balances and guarantee information for the current and previous months. It contains tabular data with monetary amounts but is very short (613 characters) and does not include comprehensive financial statements or detailed analysis. It appears to be a regulatory disclosure of specific financial information rather than a full report or announcement of a report. There is no indication of an annual or interim report, audit report, or earnings release. The content fits best as a Regulatory Filing (RNS), which is a fallback category for miscellaneous regulatory disclosures that do not fit other specific categories.
2022-05-10 Chinese
111年4月營業收入
Regulatory Filings Classification · 90% confidence The document is a revenue summary report for a specific month (April 2022) showing net operating revenue figures and percentage changes compared to the previous year. It includes explanations for revenue changes and accounting standards references (IFRS). The document length is short (799 characters) and it provides summarized financial data without detailed financial statements or comprehensive analysis. It is not a full annual or interim report, nor an earnings release with key highlights. It appears to be a regulatory or public disclosure of monthly revenue figures, typical of a regulatory filing or a brief financial update. Given the short length and nature, it fits best under Regulatory Filings (RNS) as a general regulatory announcement of financial data without full report content.
2022-05-10 Chinese
本公司腎臟新藥拿百磷 (Nephoxil) 韓國授權夥伴 「Kyowa Hakko Kirin Korea Co., Ltd.」(以下簡稱為KKKR) 取得 NDA新藥進口上市許可
Regulatory Filings Classification · 95% confidence The document is a regulatory announcement from a listed company (寶齡富錦生技股份有限公司) reporting that its Korean licensing partner has obtained NDA approval for a new drug. The content focuses on a factual event related to drug approval and licensing, with no financial statements, earnings data, or detailed report content. The document length is short (1611 characters) and it serves as a formal disclosure of a material event rather than a financial or management report. It does not fit categories like Annual Report, Earnings Release, or Management Reports. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about a significant corporate event that does not fit other specific categories.
2022-05-09 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.